Kognitic at ASCO 2026: Advancing the Future of Oncology Intelligence

Kognitic was proud to participate in ASCO 2026, the world’s leading oncology conference where clinicians, researchers, and innovators come together to shape the future of cancer care. This year’s meeting highlighted groundbreaking clinical insights, emerging therapeutic pathways, and the expanding role of AI-driven decision intelligence in oncology.

Our leadership team, including Timmy Cheedala (Chairman), Jaseem Mahmmdla (CEO), Kimon Lounis (Head of Commercial Parnerships), Hunter Moody (Head of Scientific Strategy) and senior members of the Kognitic organization, engaged with oncologists, researchers, and life-science partners from across the globe.

“Having Timmy join us at ASCO 2026 was a significant commitment from Kognitic’s leadership. His presence underscored our dedication to contributing meaningfully to the oncology community and supporting ASCO’s mission. It reinforced the importance we place on advancing evidence-based cancer care and collaborating with global experts who share that vision.” Said Jaseem Mahmmdla, CEO, Kognitic

Throughout the conference, our booth welcomed a steady stream of physicians, researchers, and industry leaders exploring how Kognitic’s platform is transforming:

We thank everyone who visited us, shared their perspectives, and explored collaboration opportunities. ASCO continues to be a powerful reminder of why we do what we do: to empower the oncology community with the intelligence needed to deliver better care, faster.

Together, we move oncology forward.